Interview with Dr Matt Dun on DIPG research and GDC-0084, page-32

im not sure what is supposed to be gained by them PT3 - we can all go back in time and cherry pick small pieces of info out of context from old releases even though the trials progress every day and new released figures and data sets are updated... below is current as of August this year.

these are the current figures from the recent annual report on PFS and OS and they are remarkable and as we read here a very good indicator of success.





what I find interesting is the constant comments around GBM Agile being a new modern trial method and this has been acknowledged by the FDA as a suitable trial structure for data to progress the drug application to commercialisation... and also that it’s cheaper and quicker.

our conservative and most excellent management responsible for our strategy adopting worlds best practice and new more effective trial methodologies is only a bonus and results are slowly being recognised - there is way more to come!

these screens show PFS & OS figures are meaningful progressions for patients with GBM and the first advancement in nearly two decades since temolozomide (discovered mid 1990’s) became the standard of care a little later post 2000

Telozolomide only works in 35% of patients Paxalisib works in well over 60% - so not only does it meaningfully extend life in those it works for - it does so in twice the number of patients!!!

surely a company performing this good work deserves support or at least a nod and move on - why anyone who does not hold would continue a campaign against their efforts is beyond me. The company does not make holders or x-holders buy or sell so disgruntled people should maybe look internally and meditate on internal decision making and internal strategy choices.

Needless to say Paxalisib is a seriously huge advancement in treatment options and is very safe and best of all oral.

really exciting times ahead for loyal investors - traders not so much and it drives them craaaaaaaaazy! Investors fund trials and build something - a benefit is created where none existed.

My dream is we benefit many many patients by funding trials and operations until the engine roars to life and takes over - we are seeing those first few revolutions as it fires up right now... the benefits to early investors who make this possible will be extraordinary